ConductScience.org, home

Paper307692

Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia.

Sachs L. Nature, 1978. Cited by 649 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia. Papers, record 307692. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/307692

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia.
PubMed
Journal
Nature
PubMed
Year
1978
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
649
iCite
Relative citation ratio, by iCite
14.2
iCite
Revised in PubMed
2024-01-09
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Sachs LL

Source PubMed

Topics19

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Cell DifferentiationMajor topic
Colony-Stimulating FactorsMajor topic
GlycoproteinsMajor topic
GranulocytesMajor topic
Hematopoietic Stem CellsMajor topic
Leukemia, MyeloidMajor topic
LeukocytesMajor topic
MacrophagesMajor topic
Animals
Bone Marrow Cells
Cell Membrane
Cells, Cultured
Chromosome Aberrations
Chromosome Disorders
Dexamethasone
Humans
Leukemia, Experimental
Lipid A
Mice

Source PubMed

Cited by102

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 649 citations.

PMIDTitleJournalYearIn PapersSource
42,232,986Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.Front Med (Lausanne)2026https://conductscience.org/library/papers/42232986PubMed
40,777,043The immunomodulatory role of tumor-initiating cells in digestive system tumors: from mechanisms to therapy.Front Immunol2025https://conductscience.org/library/papers/40777043PubMed
39,692,941Impact of prolactin treatment on enhancing the cellular responses of MCF7 breast cancer cells to tamoxifen treatment.Discov Oncol2024https://conductscience.org/library/papers/39692941PubMed
37,168,856ATRA treatment slowed P-selectin-mediated rolling of flowing HL60 cells in a mechano-chemical-dependent manner.Front Immunol2023https://conductscience.org/library/papers/37168856PubMed
36,980,800A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia.Cancers (Basel)2023https://conductscience.org/library/papers/36980800PubMed
34,938,986History of Acute Promyelocytic Leukemia.Clin Hematol Int2021https://conductscience.org/library/papers/34938986PubMed
34,193,815Acute promyelocytic leukemia current treatment algorithms.Blood Cancer J2021https://conductscience.org/library/papers/34193815PubMed
33,958,005Tumor reversion: a dream or a reality.Biomark Res2021https://conductscience.org/library/papers/33958005PubMed
33,446,633Prolactin receptor-driven combined luminal and epithelial differentiation in breast cancer restricts plasticity, stemness, tumorigenesis and metastasis.Oncogenesis2021https://conductscience.org/library/papers/33446633PubMed
33,050,159Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells.Int J Mol Sci2020https://conductscience.org/library/papers/33050159PubMed
32,824,945Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia.Cells2020https://conductscience.org/library/papers/32824945PubMed
32,700,196Acute Promyelocytic Leukemia: A History over 60 Years-From the Most Malignant to the most Curable Form of Acute Leukemia.Oncol Ther2019https://conductscience.org/library/papers/32700196PubMed
29,337,961How the evolution of multicellularity set the stage for cancer.Br J Cancer2018https://conductscience.org/library/papers/29337961PubMed
26,911,190Leukaemia 'firsts' in cancer research and treatment.Nat Rev Cancer2016https://conductscience.org/library/papers/26911190PubMed
25,821,840The "virgin birth", polyploidy, and the origin of cancer.Oncoscience2015https://conductscience.org/library/papers/25821840PubMed
25,387,435Towards a systemic paradigm in carcinogenesis: linking epigenetics and genetics.Mol Biol Rep2015https://conductscience.org/library/papers/25387435PubMed
24,938,378Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.Int J Hematol2014https://conductscience.org/library/papers/24938378PubMed
24,469,826Pioneer of hematopoietic colony-stimulating factors: Leo Sachs (1924-2013).Proc Natl Acad Sci U S A2014https://conductscience.org/library/papers/24469826PubMed
24,264,602ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells.J Cell Physiol2014https://conductscience.org/library/papers/24264602PubMed
23,521,217Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro.Cancer Sci2013https://conductscience.org/library/papers/23521217PubMed

See all 102 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/307692

GET https://conductscience.org/api/papers/v1/307692/cited_by?page=2